we have demonstrated an increase in transgene expression of more than 600-fold from a minimal simian virus 40 (SV40) promoter and an increase in expression of 200-fold from the ITR in a vector ...

The market is driven by ongoing developments in the fields of genetics and biotechnology, such as using capsid engineering to increase vector tropism and altering AAV transduction efficiency by ...

Here we show that an orally administered adeno-associated viral vector leads to persistent expression ... that scavenge foreign proteins, viruses and bacteria, and rapidly (within 3 hours ...

Adeno-associated viruses (AAV) have emerged as the lead vector in clinical trials and form the basis for several approved gene therapies for human diseases, mainly owing to their ability to sustain ...

Adeno-associated viruses (AAVs) have become highly promising tools for research and clinical applications ... We tested the transduction efficacy and specificity of each vector after stereotactic ...

Mammoth Biosciences researchers have developed NanoCas, an ultracompact CRISPR nuclease, demonstrating its ability to perform ...

AAV-Navβ1 gene therapy effectively reduces seizures and prolongs life in a mouse model of SCN1B-linked Dravet syndrome, ...

Researchers from Tikkunlev Therapeutics Inc. and the University of Utah have presented preclinical data on TLT-101, a gene therapy consisting of an adeno-associated virus serotype 9 (AAV9) vector ...

The AAV Innovation Summit 2025, hosted by Form Bio, will bring together top experts in gene therapy to discuss the latest advancements in adeno-associated virus (AAV) therapeutics. The event, set for ...